Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma

被引:3
|
作者
Li, Xiumei [1 ]
Chen, Jianwei [2 ]
Zhang, Chengxiu [3 ]
Han, Zewen [1 ]
Zheng, Xiuying [1 ]
Cao, Dairong [1 ,4 ,5 ,6 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Fuzhou 350005, Fujian, Peoples R China
[2] Fujian Prov Canc Hosp, Dept Pathol, Fuzhou 350014, Fujian, Peoples R China
[3] East China Normal Univ, Sch Phys & Elect Sci, Shanghai Key Lab Magnet Resonance, Shanghai 200062, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Radiol, Binhai Campus, Fuzhou 350212, Fujian, Peoples R China
[5] Fujian Med Univ, Affiliated Hosp 1, Fujian Key Lab Precis Med Canc, Fuzhou 350005, Fujian, Peoples R China
[6] Fujian Med Univ, Affiliated Hosp 1, Key Lab Radiat Biol, Fujian Higher Educ Inst, Fuzhou 200062, Peoples R China
关键词
Lung adenocarcinoma; Radiomics; Computed tomography; T790M; CANCER;
D O I
10.1186/s12890-023-02609-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundThe purpose of this study was to develop a radiomic nomogram to predict T790M mutation of lung adenocarcinoma base on non-enhanced CT lung images.MethodsThis retrospective study reviewed demographic data and lung CT images of 215 lung adenocarcinoma patients with T790M gene test results. 215 patients (including 52 positive) were divided into a training set (n = 150, 36 positive) and an independent test set (n = 65, 16 positive). Multivariate logistic regression was used to select demographic data and CT semantic features to build clinical model. We extracted quantitative features from the volume of interest (VOI) of the lesion, and developed the radiomic model with different feature selection algorithms and classifiers. The models were trained by a 5-fold cross validation strategy on the training set and assessed on the test set. ROC was used to estimate the performance of the clinical model, radiomic model, and merged nomogram.ResultsThree demographic features (gender, smoking, emphysema) and ten radiomic features (Kruskal-Wallis as selection algorithm, LASSO Logistic Regression as classifier) were determined to build the models. The AUC of the clinical model, radiomic model, and nomogram in the test set were 0.742(95%CI, 0.619-0.843), 0.810(95%CI, 0.696-0.907), 0.841(95%CI, 0.743-0.938), respectively. The predictive efficacy of the nomogram was better than the clinical model (p = 0.042). The nomogram predicted T790M mutation with cutoff value was 0.69 and the score was above 130.ConclusionThe nomogram developed in this study is a non-invasive, convenient, and economical method for predicting T790M mutation of lung adenocarcinoma, which has a good prospect for clinical application.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
    Zang, Shu-Zhi
    Yang, Yan-Rong
    Zhao, Sha-Sha
    Li, Yun-Xia
    Gao, Xin-Yuan
    Zhong, Chun-Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (05) : 1735 - 1740
  • [42] Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features
    Zhang, Huiyuan
    Meng, Xiangxi
    Wang, Zhe
    Zhou, Xin
    Liu, Yang
    Li, Nan
    DIAGNOSTICS, 2025, 15 (05)
  • [43] Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma
    Yang, Chunsheng
    Chen, Weidong
    Gong, Guanzhong
    Li, Zhenjiang
    Qiu, Qingtao
    Yin, Yong
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (11) : 6683 - 6690
  • [44] The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Chen, Kun-Chieh
    Hsu, Chia-Hung
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chen, Huei-Wen
    Yu, Sung-Liang
    Yang, Tsung-Ying
    Chang, Gee-Chen
    CANCER RESEARCH AND TREATMENT, 2018, 50 (04): : 1294 - 1303
  • [45] Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
    Nasu, Shingo
    Shiroyama, Takayuki
    Morita, Satomu
    Takata, So
    Takada, Himmune
    Masuhiro, Kentaro
    Tanaka, Ayako
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Hirashima, Tomonori
    INTERNAL MEDICINE, 2018, 57 (24) : 3643 - 3645
  • [46] The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
    Cheng, Wen-Chien
    Hsia, Te-Chun
    Tu, Chih-Yen
    Chen, Hung-Jen
    ONCOTARGETS AND THERAPY, 2020, 13 : 13425 - 13435
  • [47] Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
    Zhang, Ping
    Nie, Xin
    Wang, Bing
    Li, Lin
    THORACIC CANCER, 2018, 9 (12) : 1774 - 1777
  • [48] Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging
    Goggi, Julian L.
    Haslop, Anna
    Ramasamy, Boominathan
    Cheng, Peter
    Jiang, Lingfan
    Soh, Vanessa
    Robins, Edward G.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 (09) : 596 - 603
  • [49] A Case of Adenocarcinoma of the Lung With EGFR T790 Mutation Presenting With Chylous Ascites
    Nakashima, Kentaro
    Hara, Yu
    Sato, Takashi
    Shinkai, Masaharu
    Kaneko, Takeshi
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1227 - 1228
  • [50] Development of a novel nomogram-based model incorporating 3D radiomic signatures and lung CT radiological features for differentiating invasive adenocarcinoma from adenocarcinoma in situ and minimally invasive adenocarcinoma
    Ren, He
    Xiao, Zhengguang
    Ling, Chen
    Wang, Jiayi
    Wu, Shiyu
    Zeng, Yanan
    Li, Ping
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2023, 13 (01) : 237 - 248